TheraTech Inc. (NASDAQ:THRT) announced Tuesday that it hasfiled an application with the FDA for approval of itstransdermal nitroglycerin patch for treating angina. The SaltLake City firm said that it is preparing to file a Europeancounterpart.
The product incorporates TheraTech's enhancer technology thatallows bioequivalent dose administration from smaller patchesthan the products already on the market. TheraTech willproduce the product in its new manufacturing facility, whichshould be completed by 1994.
(c) 1997 American Health Consultants. All rights reserved.